BCYC
Price
$7.99
Change
-$0.53 (-6.22%)
Updated
Aug 1 closing price
Capitalization
553.34M
89 days until earnings call
PVLA
Price
$36.55
Change
-$0.03 (-0.08%)
Updated
Aug 1 closing price
Capitalization
404.42M
Interact to see
Advertisement

BCYC vs PVLA

Header iconBCYC vs PVLA Comparison
Open Charts BCYC vs PVLABanner chart's image
Bicycle Therapeutics
Price$7.99
Change-$0.53 (-6.22%)
Volume$151.22K
Capitalization553.34M
Palvella Therapeutics
Price$36.55
Change-$0.03 (-0.08%)
Volume$56.13K
Capitalization404.42M
BCYC vs PVLA Comparison Chart in %
Loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PVLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. PVLA commentary
Aug 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and PVLA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (BCYC: $7.99 vs. PVLA: $36.55)
Brand notoriety: BCYC and PVLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 54% vs. PVLA: 39%
Market capitalization -- BCYC: $553.34M vs. PVLA: $404.42M
BCYC [@Biotechnology] is valued at $553.34M. PVLA’s [@Biotechnology] market capitalization is $404.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $213.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whilePVLA’s FA Score has 1 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • PVLA’s FA Score: 1 green, 4 red.
According to our system of comparison, PVLA is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 7 TA indicator(s) are bullish while PVLA’s TA Score has 3 bullish TA indicator(s).

  • BCYC’s TA Score: 7 bullish, 3 bearish.
  • PVLA’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, BCYC is a better buy in the short-term than PVLA.

Price Growth

BCYC (@Biotechnology) experienced а -8.16% price change this week, while PVLA (@Biotechnology) price change was -5.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.14%. For the same industry, the average monthly price growth was +15.55%, and the average quarterly price growth was +36.18%.

Reported Earning Dates

BCYC is expected to report earnings on Oct 30, 2025.

PVLA is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (+0.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCYC($553M) has a higher market cap than PVLA($404M). PVLA YTD gains are higher at: 204.583 vs. BCYC (-42.929). PVLA has higher annual earnings (EBITDA): -18.36M vs. BCYC (-200.61M). BCYC has more cash in the bank: 793M vs. PVLA (75.6M). BCYC has higher revenues than PVLA: BCYC (25.7M) vs PVLA (0).
BCYCPVLABCYC / PVLA
Capitalization553M404M137%
EBITDA-200.61M-18.36M1,093%
Gain YTD-42.929204.583-21%
P/E RatioN/A14.22-
Revenue25.7M0-
Total Cash793M75.6M1,049%
Total Debt8.33MN/A-
FUNDAMENTALS RATINGS
BCYC vs PVLA: Fundamental Ratings
BCYC
PVLA
OUTLOOK RATING
1..100
1819
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
66
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
6235
P/E GROWTH RATING
1..100
10010
SEASONALITY SCORE
1..100
45n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (21) in the null industry is somewhat better than the same rating for PVLA (66). This means that BCYC’s stock grew somewhat faster than PVLA’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as PVLA (100). This means that BCYC’s stock grew similarly to PVLA’s over the last 12 months.

BCYC's SMR Rating (96) in the null industry is in the same range as PVLA (100). This means that BCYC’s stock grew similarly to PVLA’s over the last 12 months.

PVLA's Price Growth Rating (35) in the null industry is in the same range as BCYC (62). This means that PVLA’s stock grew similarly to BCYC’s over the last 12 months.

PVLA's P/E Growth Rating (10) in the null industry is significantly better than the same rating for BCYC (100). This means that PVLA’s stock grew significantly faster than BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCPVLA
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 11 days ago
82%
Bullish Trend 10 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PVLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PESPX28.67N/A
N/A
BNY Mellon MidCap Index Inv
GSIOX27.92N/A
N/A
Goldman Sachs Small Cap Gr Insghts Instl
QCSGX20.98N/A
N/A
Federated Hermes MDT Small Cap Growth C
TRGZX37.78N/A
N/A
T. Rowe Price Emerging Markets Stock Z
RALYX10.57N/A
N/A
Lazard Real Assets R6